ABIO - ARCA biopharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

ARCA biopharma, Inc.

11080 CirclePoint Road
Suite 140
Westminster, CO 80020
United States

Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael R. Bristow M.D., Ph.D.Co-Founder, Chief Exec. Officer, Pres and Director402.56kN/A1945
Mr. Thomas A. KeuerChief Operating Officer365.83kN/A1959
Mr. Christopher D. OzeroffSr. VP, Gen. Counsel and Sec.346.87kN/A1959
Mr. Brian L. SelbyChief Accounting Officer and VP of Fin.N/AN/A1962
Monique PlamondonVP of Regulatory Affairs & QAN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Corporate Governance

ARCA biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.